Supplements Stack¶

Overview¶

This is a project-generic catalog of compounds with documented activity on NLRP3, urate, or related inflammation pathways. It is not a recommended stack. Each compound has trade-offs that depend on context — sex, genetics (notably ABCG2 Q141K and androgen-axis state), comorbidities, current medications, and interactions with other compounds in this catalog. Read individual entries for contraindications, drug interactions, dose-dependent risk, and stack-level antagonisms before considering use.

This catalog is not a replacement for medical care. Work with a physician on any of these compounds, especially those with drug interactions or dose-ceiling concerns.

TCM lineage note: Several compounds in this catalog have explicit TCM materia medica lineage — oridonin (Rabdosia rubescens / Dong Ling Cao 冬凌草), EGCG (green tea / Lu Cha 绿茶), theaflavins (black tea / Hong Cha 红茶), berberine (Coptis chinensis / Huang Lian 黄连), resveratrol (Polygonum cuspidatum / Hu Zhang 虎杖), curcumin (turmeric / Jiang Huang 姜黄). The methodology for applying modern scientific rigor to these compounds — including chokepoint mapping, ChEMBL cross-check, bioavailability-honest framing, and formula decomposition — is formalized in tcm-modern-rigor-intersection.md. (source: tcm-modern-rigor-intersection.md)

Species-gap caveat (methodological standard, 2026-04-23): Rodent cellular IC50 values for NLRP3 inhibitors routinely diverge from human cellular IC50 by up to 3 orders of magnitude. Example: dapansutrile IC50 = 1 nM in mouse J774A.1 cells vs. 1,000 nM (1 μM) in human MDM cells under LPS+nigericin stimulation (ChEMBL v34). Every rodent-derived IC50 in this document should be read with that translation uncertainty in mind. When evaluating new compounds, prefer human-cell (THP-1, PBMC, human MDM) data over rodent cellular assays. (source: chembl-cross-check.md)

Per-entry template (standardized 2026-04-25): Each compound entry below uses a fixed template — Mechanism, Evidence level, Population context, Dosing range, Contraindications, Drug interactions, Dose-dependent risk profile, Stack interactions (within this catalog), Cost. The Stack-interactions field is the cross-link to abcg2-modulators.md, androgen-urate-axis.md, and the Stack-level interactions section near the bottom of this page. Several compounds in this catalog are functional ABCG2 inhibitors at typical supplement doses and may pharmacologically antagonize the gut-lumen-sink thesis in androgen-dominant or Q141K-positive readers — see the "Stack-level contradictions" subsection.

Where to start (triage by situation)¶

This catalog is compound-first. If you arrived with "I have gout, what do I do?" and want a situation-first entry surface — what to start today, what to build out over a month, what to plan for over a year — read gout-action-guide.md first. It triages by patient situation (default-male, androgen-elevated, Q141K-positive, active flare, on allopurinol, prevention) and links back into the per-compound entries below for depth.

Use this catalog when you've already identified a candidate compound and want full mechanism, dose, contraindications, drug interactions, and stack-level antagonism details. Each entry below has all of that.

Use the action guide when you don't yet know which compound is right for your situation, or when you're new to the project and want a 5-minute orientation rather than a 1,100-line catalog read.

The two surfaces are linked — every action-guide compound entry points back here for compound depth, and major catalog updates (new compound additions, dose revisions, contraindication updates) need to propagate to the action guide. The propagation is currently manual; see synthesis/strategic-reflections/ for the planned fresh-stack.py discipline that will eventually formalize it.

Section 1: NOW (Available Today)¶

Compounds currently accessible, with strong evidence, that can be started immediately.

Beta-Hydroxybutyrate (BHB) / Exogenous Ketones¶

Category: Metabolite / Supplement

Mechanism: Direct NLRP3 inflammasome inhibitor; blocks priming (CP1), assembly (CP2), and ASC speck formation (CP3)

Evidence level: Established (Nature Medicine study: BHB-specific NLRP3 inhibition in neutrophils)

Population context: Broad applicability. Sex-neutral mechanism (NLRP3 inhibition is not androgen-axis-modulated). Caution in T1DM (ketoacidosis risk distinct from physiological ketosis). Pregnancy: ketogenic dietary patterns are debated for fetal substrate provision; exogenous ketone supplementation in pregnancy is unstudied. Patients with metabolic flexibility issues (e.g., long-chain fatty acid oxidation defects) should avoid MCT-based ketosis.

Dosing range: - Ketogenic diet (endogenous BHB production): maintain 2–5 mM serum ketones via carb restriction (~<50g/day) - Exogenous ketones (ketone salts or esters): 10–20g BHB/day - MCT oil as alternative: 1–2 tbsp (~15–30g) daily generates ketones via beta-oxidation

Key insight: BHB doesn't require fasting or strict keto to work — it acts directly as a signaling molecule on NLRP3 regardless of metabolic pathway. (Source: nlrp3-exploit-map.md)

Contraindications: Active gout flare (transient UA rise from ketosis; see dose-dependent risk). T1DM without close glucose monitoring. Pregnancy (insufficient data on exogenous ketone safety). Severe hepatic disease (impaired ketone metabolism). Carnitine-deficiency syndromes if using MCT-based induction.

Drug interactions: - SGLT2 inhibitors (canagliflozin, empagliflozin, dapagliflozin): additive ketosis; euglycemic diabetic ketoacidosis risk in T2DM patients on these drugs. - Insulin / insulin secretagogues: dietary ketosis lowers glucose requirements; dose adjustment needed to avoid hypoglycemia. - Acetazolamide / topiramate / zonisamide: carbonic anhydrase inhibitors compound metabolic acidosis risk on ketogenic regimens.

Dose-dependent risk profile: - 5–20g/day exogenous BHB: well-tolerated; GI upset is the main side effect (most common with ketone salts; mineral load matters). - >30g/day or aggressive nutritional ketosis: transient serum UA rise of 5–10% (ketone bodies and urate compete for renal MCT/URAT1 reabsorption). This is the gout-relevant dose ceiling. Sustained nutritional ketosis can also produce mild hyperuricemia for the same reason. - MCT >2 tbsp at one sitting: GI distress is the practical limiter.

Stack interactions (within this catalog): - Antagonism with intermittent fasting during active flares: both ketogenic states transiently raise serum UA via competition for renal urate excretion; layering fasting on top of exogenous ketones during a flare amplifies the spike. - Synergy with NAC, omega-3: BHB-driven NLRP3 inhibition (CP1–CP3) is mechanistically additive with NAC's glutathione/ROS axis (CP2) and omega-3 SPM-driven resolution (CP5). - No ABCG2 interaction documented. Neutral on the gut-lumen-sink axis.

Cost: Negligible (dietary) to $20–40/month (ketone salts)

Intermittent Fasting¶

Category: Behavioral / Lifestyle

Mechanism: Induces AMPK activation, mTOR inhibition, autophagy upregulation; generates endogenous BHB

Evidence level: Established (extensive longevity literature)

Population context: Sex-differential effects documented. Women of reproductive age may experience HPO axis disruption (cycle irregularity, lowered LH/FSH) at aggressive fasting protocols (>20 hour windows or sustained <1500 kcal/day); men tolerate longer windows with less reproductive-axis disruption. Underweight, history of eating disorder, or pregnancy: contraindicated. Adolescents: not appropriate. Older adults (>70): protein-sparing windows preferred over true fasts.

Dosing range: - Minimum: 16:8 (16-hour fast, 8-hour eating window) - Optimal for NLRP3: 24-hour fasts periodically (weekly or biweekly) - Examples: dinner-to-dinner, breakfast-to-breakfast

Contraindications: Active gout flare (precipitates hyperuricemia worsening). Pregnancy and lactation. T1DM without endocrinology supervision. History of eating disorder. Underweight (BMI <18.5). Adrenal insufficiency. Concurrent fluoroquinolone therapy in older adults (tendinopathy risk amplified by catabolic states).

Drug interactions: - Sulfonylureas / insulin: hypoglycemia risk; dose timing must shift. - Levothyroxine: absorption window shifts can affect TSH stability; consistent dosing time relative to feeding window matters more than the specific time. - Metformin: typically well-tolerated; some lactic acidosis case reports under prolonged fasts in CKD. - Drugs that must be taken with food (e.g., HIV protease inhibitors, some statins): schedule conflicts with fasting window.

Dose-dependent risk profile: - 16:8 daily: well-tolerated by most; minimal UA effect outside flares. - 24-hour fast weekly: transient UA rise of ~0.5–1.0 mg/dL during the fast (ketone competition for renal excretion); resolves on refeed. - 48–72 hour fast: substantial UA spikes (1–2 mg/dL) and increased flare risk in known gout patients. Ceiling for gout-relevant use is at most one 24-hour fast per week, scheduled away from prodrome periods.

Stack interactions (within this catalog): - Antagonism (acute, during flare): as with BHB, transient UA rise during the fasting window can precipitate flares — do not combine fasting with exogenous BHB during prodrome or active flare. - Synergy (autophagy axis): layered with spermidine/trehalose from fermented foods, both push the same TFEB/autophagy axis (CP2/CP3). - Synergy with engineered uricase (future): fasting-induced UA spikes are the precise scenario where a gut-lumen uricase sink would buffer the pathophysiology.

Cost: Free

KPV Nasal Spray¶

Category: Peptide

Mechanism: α-MSH C-terminal tripeptide (Lys-Pro-Val); stabilizes IκB-α → prevents NF-κB nuclear translocation (CP1)

Evidence level: Supported (Published research in gout-specific context: (CKPV)₂ reverses inflammatory effect of urate crystals)

Population context: Broad applicability. No documented sex-differential effect. α-MSH-derived peptides have melanocyte-stimulating activity at high systemic doses; intranasal route at the doses listed is well below that threshold. Caution in patients with melanoma history (theoretical, mechanism-extrapolated rather than clinically observed at these doses).

Dosing range: 200–500 mcg/day intranasal

Administration: - Morning spray (nasal mucosa, high PepT1 expression) - Combine timing with BPC-157 spray for convenience

Contraindications: Active or recent melanoma (theoretical, based on α-MSH/MC1R signaling). Pregnancy (insufficient data). Pediatric use (insufficient data). Sourcing-quality unknowns: research peptide suppliers vary widely in purity and endotoxin load.

Drug interactions: - Immunosuppressants (tacrolimus, cyclosporine, biologics): unstudied; mechanism overlap with NF-κB pathway. - Topical/intranasal corticosteroids: mechanism overlap; no clear pharmacological conflict but redundant signaling. - No documented small-molecule drug interactions; peptide is rapidly hydrolyzed.

Dose-dependent risk profile: - 200–500 mcg/day intranasal: well-tolerated in published research; main risk is sourcing quality. - Systemic dosing (subcutaneous, off-label) at multi-mg levels: melanocyte effects (skin darkening) become detectable. Stay intranasal at the doses listed. - Sourcing: research peptide suppliers without third-party HPLC/MS/endotoxin verification carry product-quality risk that scales with dose and frequency.

Stack interactions (within this catalog): - Synergy with BPC-157 (non-overlapping pathways): both small peptides, complementary mechanisms — KPV at NF-κB priming (CP1), BPC-157 at cytoprotection / NO modulation. - Mild redundancy with sulforaphane, EGCG, quercetin: all converge on NF-κB / NLRP3 priming axes; cumulative benefit unclear vs. single-agent. - No ABCG2 interaction. Peptide does not engage transporter axis.

Cost: $100–200/month (Peptides@BioTechPackage, GenScript, or research peptide custom synthesis)

BPC-157 Nasal Spray¶

Category: Peptide / Tissue Repair

Mechanism: - Cytoprotective (protects macrophages from MSU crystal-induced damage) - Nitric oxide system modulation - CP1 + tissue repair (secondary mechanism)

Evidence level: Established (published literature; you're already using this)

Population context: Broad applicability. No documented sex-differential effect. Most published data is in rodent injury models; human use is largely off-label and based on mechanistic extrapolation from cytoprotection literature. The peptide's growth-promoting / angiogenic effects raise theoretical concerns in active malignancy (mechanism-extrapolated, not clinically demonstrated).

Dosing range: 200–500 mcg/day intranasal

Contraindications: Active malignancy (theoretical, based on angiogenic signaling — not clinically demonstrated). Pregnancy (insufficient data). Sourcing-quality unknowns as with KPV.

Drug interactions: - Anti-VEGF agents (bevacizumab): theoretical antagonism; BPC-157 promotes angiogenesis. - Immunosuppressants: unstudied. - No documented small-molecule interactions at standard intranasal dosing.

Dose-dependent risk profile: - 200–500 mcg/day intranasal: well-tolerated, clinical safety established at this range. - Higher doses (multi-mg systemic, IM injection): pushes into less-characterized territory; main risk is sourcing-quality variability. - Long-term continuous use beyond 6 months has minimal published human safety data — pulse dosing or treatment cycles are conservative.

Stack interactions (within this catalog): - Synergy with KPV (non-overlapping): see KPV entry. - Synergy with omega-3 SPMs: both promote resolution-phase tissue repair (efferocytosis, M1→M2 switching). - No ABCG2 interaction.

Cost: Existing supply (continue current)

Sulforaphane (Broccoli Sprouts)¶

Category: Phytonutrient

Mechanism: Activates Keap1-Nrf2 pathway → master regulator of cellular antioxidant defense; cross-talk with NF-κB (CP1/CP2). Sub-μM Nrf2 activation: EC50 = 580 nM (J Med Chem 2019, ChEMBL) — rare potency for a food-derived compound. ABCG2 induction bonus: Sulforaphane activates Nrf2 in enterocytes → upregulates intestinal ABCG2 expression, increasing gut urate secretion capacity (In Vitro + Animal Model; source: abcg2-modulators.md). This makes sulforaphane the only stack compound that simultaneously suppresses NLRP3 priming (CP1/CP2) AND enhances the gut-lumen sink substrate supply.

Evidence level: Established (Nrf2 activation) + Animal Model hyperuricemia (2026-04-23 re-audit, PROMOTED from Tier 4) — Wang 2022 J Adv Res (PMID 36371056): sulforaphane decreased urate synthesis + increased renal urate excretion + Nrf2-mediated epigenetic modification in hyperuricemic rats. This bridges the uric-acid and inflammation axes in a single compound. The prior "no gout-specific evidence" framing was keyword-gated on "gout" in abstracts and missed the hyperuricemia rat model. (source: nlrp3-inhibitor-screen.md 2026-04-23 re-audit) Upgraded to Tier 2 on 2026-05-05 with two additional citations: Yang 2018 Rheumatology (Oxford) (PMID 29340626) — oral SFN attenuated MSU-crystal-induced foot-pad swelling and air-pouch acute gout in mice (Animal Model, oral); Greaney 2015 J Leukoc Biol (PMID 26269198) — sulforaphane inhibits NLRP1, NLRP3, NAIP5/NLRC4, and AIM2 inflammasomes independent of Nrf2 in macrophages and in vivo acute gout peritonitis. Adds a direct caspase-1 / inflammasome-assembly mechanism distinct from the Nrf2 → ABCG2 / NF-κB axis.

Population context: Broad applicability. Animal-model UA evidence is in male rats; sex-differential effect on urate axis is not characterized. Goitrogenic effect of cruciferous glucosinolates is dose-dependent and clinically negligible at supplement-relevant doses, but patients with overt iodine deficiency or untreated hypothyroidism may want iodine adequacy in parallel. Hashimoto's patients: cruciferous goitrogen concern is largely overstated at dietary doses but present at concentrated extract doses.

Dosing range: - Raw broccoli sprouts: 100–150g/day (contains glucoraphanin + myrosinase) - Must be raw/freshly chopped — cooking kills myrosinase and defeats the mechanism - Chewing or blending activates the conversion: glucoraphanin → sulforaphane - Sulforaphane supplement: ~50 mg/day (extract or stabilized form) - Bioavailability hack: If using cooked broccoli, add mustard seed powder (~1–2 tsp) to restore myrosinase activity - Highest bioavailability: Freeze-dried broccoli sprout powder with active myrosinase in capsule form

Contraindications: Untreated hypothyroidism with iodine deficiency (theoretical, dose-dependent goitrogen effect). Severe G6PD deficiency (Nrf2 activators interact with the glutathione pathway — clinically minor at supplement doses but worth noting). Pregnancy: dietary intake fine; concentrated extract doses unstudied.

Drug interactions: - Acetaminophen (paracetamol): sulforaphane upregulates phase II detox enzymes including glutathione synthesis — theoretically protective against acetaminophen hepatotoxicity rather than antagonistic, but quantitative impact is small. - CYP3A4 substrates with narrow therapeutic index: sulforaphane modestly induces phase II conjugation; minor effect on CYP3A4-cleared drugs (tacrolimus, cyclosporine, some statins) is theoretically possible but clinically not significant at dietary or supplement doses. - Levothyroxine: dietary cruciferous intake at any reasonable level is fine; theoretical iodine-uptake competition is overstated.

Dose-dependent risk profile: - 50 mg/day sulforaphane equivalent or 100–150g/day raw sprouts: well-tolerated; standard supplement range. - Concentrated extracts >100 mg/day: GI upset, sulfurous breath/body odor; theoretical goitrogen effect approaches clinical relevance but still small in iodine-replete individuals. - Raw broccoli >300g/day chronic: goitrogen effect becomes clinically detectable in iodine-deficient individuals.

Stack interactions (within this catalog): - Stack synergy (Nrf2 activator cluster): sulforaphane + quercetin + oridonin all activate Nrf2 — cumulative effect at the Nrf2 axis but diminishing-returns regime; combining all three is redundant rather than additive at the maximal-effect ceiling. - ABCG2 axis: Nrf2 activation transcriptionally induces ABCG2 in enterocytes (gut-selective at moderate; also induces hepatic and BBB Nrf2-driven targets at high systemic exposure). Per abcg2-modulators.md, sulforaphane is a Tier 1 inducer of the gut urate sink — synergistic with the platform thesis rather than antagonistic. Distinct from curcumin/quercetin/EGCG/genistein which are functional inhibitors of the same transporter. - Synergy with NAC: both push the glutathione/Nrf2 axis (CP2).

Cost: $5–10/week (raw sprouts) or $20–30/month (supplement)

Theaflavins (Black Tea Polyphenols) — ADDED 2026-05-05¶

Category: Phytonutrient / NLRP3 inhibitor / multi-transporter renal urate handling

Mechanism: Theaflavins are dimeric polyphenols formed when EGCG and ECG are oxidized by polyphenol oxidase during black-tea fermentation; they are the dominant red-orange pigments of black tea, oolong, and pu'er. Mechanism is distinct from EGCG: theaflavins disrupt the NLRP3-NEK7 interaction downstream of mitochondrial ROS suppression (CP2/CP3 — assembly-step), whereas EGCG's dominant route is proteasome-mediated IκB stabilization (CP1a). Unique to theaflavins in the OE stack: simultaneous downregulation of URAT1 + GLUT9 (apical and basolateral renal urate reabsorption) and upregulation of OAT1/OCTN1/OAT2/Oct½ (proximal-tubule secretion) — the only multi-transporter renal urate handling compound in the stack besides carnosine, and without carnosine's serum-carnosinase clearance ceiling. Secondary CP1a coverage via TNFSF14/HVEM modulation (TF3 specifically; Hosokawa 2010 PMID 20461739 — already cited in tnfsf14-gout-target.md).

Evidence level: - In vitro: Chen 2023 Acta Pharmacol Sin (PMID 37221235) — 50–200 μM theaflavin dose-dependently inhibited NLRP3 inflammasome activation in LPS-primed macrophages stimulated with MSU crystals, ATP, or nigericin; suppressed ASC speck formation, caspase-1 p10 cleavage, GSDMD-NT pyroptosis, and IL-1β release. Mechanism: protected mitochondrial function, reduced mtROS, blocked NLRP3-NEK7 interaction. (In Vitro) - Animal Model (oral, MSU peritonitis): Same Chen 2023 paper — oral theaflavin significantly attenuated MSU-induced mouse peritonitis (acute-gout-flare proxy model). (Animal Model) - Mechanism review: Chen 2023 Phytomedicine (PMID 36990009) — comprehensive anti-gout mechanism review covering URAT1/GLUT9 downregulation + OAT1/OCTN1/OAT2 upregulation + network-pharmacology prediction (ABCB1, MAPK14, TERT, STAT1, MMP2/14, BCL2 as anti-gout targets). - No human gout RCT exists. Cardiovascular and lipid trials (700–2,500 mg/day theaflavin-enriched extract for 12+ weeks) establish a safety baseline at typical supplement doses.

Population context: Broad applicability. The unique URAT1 angle is particularly relevant for under-excreter phenotypes (URAT1 hyperactivity-driven hyperuricemia, the male-predominant subtype documented in androgen-urate-axis.md). No documented sex-differential effect specific to theaflavins.

Dosing range: - Theaflavin-enriched extract: 200–500 mg/day, standardized to 30–80% theaflavins. TF3 (theaflavin-3,3'-digallate) is the most potent fraction; some commercial products specify TF3 content separately. - Black tea: 4–6 cups/day delivers ~50–150 mg theaflavins. Pu'er > black > oolong on a per-gram-leaf basis. - Combine with EGCG, not substitute: mechanism-orthogonal at NLRP3; additive when stacked.

Contraindications: Pregnancy (concentrated extract doses unstudied; dietary intake fine). Iron-deficiency anemia (theaflavins, like other tannins, chelate non-heme iron — separate from iron-containing meals or supplements by ≥1 hour).

Drug interactions: - CYP3A4 substrates with narrow therapeutic index: weak inhibition (similar to other tea polyphenols); minor effect at supplement doses for tacrolimus, cyclosporine, simvastatin. - Iron supplements / iron-rich meals: spaced dosing required. - Caffeine confounder: black tea contains caffeine; concentrated theaflavin extracts may or may not be decaffeinated — check the label.

Dose-dependent risk profile: - 200–500 mg/day theaflavin-enriched extract: well-tolerated at supplement range based on cardiovascular trial data. - >1,000 mg/day chronic: GI upset (tannin-driven), possible iron-status drift; not gout-specific risk.

Stack interactions (within this catalog): - EGCG (additive, not redundant): EGCG and theaflavins overlap on TNFSF14/HVEM but the dominant non-redundant activities are different (EGCG → proteasome 86 nM; theaflavins → URAT1/inflammasome assembly). Combining adds CP1a + CP2/CP3 + URAT1 coverage. Strong recommended pairing. - Carnosine (overlap at URAT1 — pick one): both downregulate URAT1 in animal models. Theaflavins do not face the carnosinase clearance ceiling. Diminishing returns if stacked at maximum dose; pick one for the URAT1 axis — theaflavins are favored if the carnosinase question is unresolved. - Sulforaphane / quercetin / oridonin (Nrf2 axis): theaflavins do not strongly activate Nrf2. Mechanism-orthogonal — combine without redundancy. - No ABCG2 interaction documented. Theaflavins are not on the curcumin/quercetin/EGCG/genistein ABCG2 functional-inhibitor list per abcg2-modulators.md, but a direct theaflavin-on-ABCG2 study has not been done.

Cost: $20–40/month for theaflavin-enriched supplement (300 mg/day). ~$10/week if relying on brewed black tea.

Reference: theaflavins.md for the full dossier including TF1/TF2A/TF2B/TF3 sub-fraction context, formulation strategies, and open questions.

Houttuynia cordata Polysaccharide (HCP / HCPM / 鱼腥草 / どくだみ) — Dual-Chokepoint Candidate (added 2026-05-19)¶

Category: Dietary polysaccharide / Multi-chokepoint (CP0 + CP1) / Research-stage

HCP is the first dietary polysaccharide in the OE corpus with documented activity at both the upstream-complement chokepoint (CP0: CH50 79-318 µg/mL across crude + purified fractions, multi-target C2 + C4 + C5; comp-018 Phase 2 anchor) and the NLRP3-priming chokepoint (CP1: intestinal tight junction restoration + NLRP3/caspase-1/IL-1β suppression in vivo; TLR4-MD2 direct binding via molecular docking + TAK-242 antagonist rescue; Treg/Th17 rebalance via gut-lung axis). The mechanism is structurally and receptor-class-distinct from mushroom β-glucans (which engage Dectin-1) — HCP engages TLR4 partial-agonism / hormetic competitive antagonism in disease-context inflammation.

Best-anchored preparation: 19.1 kDa homogeneous HCPM fraction (Chen Daofeng / Lishuang Zhou, Fudan University). Crude HCP and the 60 kDa HCP-2 homogalacturonan fraction have different (and sometimes opposite) directional effects — see Consumer-product caveat below.

Primary evidence: Li et al. 2025 Acta Pharm Sin B (PMC12254813, H1N1+MRSA coinfection mouse — single-paper dual CP0+CP1 demonstration, MCC950 rescue confirms NLRP3 on the mechanistic path); Yu et al. 2026 Biomedicines (PMC12937656, TLR4-MD2 direct binding via docking + antagonist rescue); Chen et al. 2019 Chin J Nat Med (PMC7128561, gut barrier + microbiota modulation). Evidence tier: Animal Model + In Vitro for dual-mechanism; Mechanistic Extrapolation for gout-specific MSU activity (no MSU peritonitis study located).

Consumer-product caveat — structure-dependent activity (critical): like medicinal-mushroom β-glucans (per medicinal-mushroom-complement-track.md §"Consumer-product caveat"), HCP activity is structure-dependent. Purified 60 kDa homogalacturonan HCP-2 fraction is pro-inflammatory on naïve human PBMCs in vitro (Cheng 2014 PMC7112369) via TLR4. The in vivo anti-inflammatory phenotype emerges in the context of pre-existing inflammation (LPS challenge, viral coinfection). Commercial Houttuynia capsules with undisclosed polysaccharide-fraction composition cannot be assumed equivalent to the Chen group HCPM preparation. Dosing on naïve baseline may trigger transient pro-inflammatory cytokine secretion before context-shifting to anti-inflammatory in inflamed-state physiology.

Dietary access: Houttuynia leaves are consumed widely in China (鱼腥草, "fishy-smelling herb"), Japan (どくだみ, dokudami), Korea, and Vietnam (diếp cá). Whole-plant preparations are common in TCM (清热解毒 heat-clearing toxin-eliminating formulae). No commercial purified-HCPM product currently available — getting the Chen group's HCPM fraction would require sourcing from a research-grade supplier or replicating the purification protocol.

Untested in MSU-NLRP3 (gout-specific) model — mechanistic extrapolation only. Wet-lab MSU peritonitis test is the obvious next step.

Cross-references: complement-c5a-gout.md §9.7 (CP0 mechanism + CP1 extension), nlrp3-exploit-map.md §CP1 (Houttuynia entry), upstream-complement-modulator-sweep-computational.md (comp-018 Phase 2 Tier 1d), logs/houttuynia-cp1-dual-mechanism-lit-scan-2026-05-19.md.

Oridonin (Rabdosia rubescens Extract)¶

Category: Natural Compound / NLRP3 Inhibitor (direct, curated in ChEMBL)

Mechanism: Covalently binds Cys279 in NLRP3 NACHT domain (Michael addition); blocks NLRP3-NEK7 interaction (CP2). Also activates Nrf2 and suppresses NF-κB (CP1/CP2).

Evidence level: Established — Nature Communications 2018 (cell-free / mouse covalent-binding kinetics at 0.5–2 µM); curated human THP-1 cellular IC50 = 5.18 μM per ChEMBL v34 (Eur J Med Chem 2023, 2026-04-23 MCP cross-check). The two figures measure different things — 0.5–2 μM is covalent-binding potency in cell-free / mouse assays; 5.18 μM is human cellular IC50. Oridonin is one of only two compounds in the full wiki stack with a curated direct human NLRP3 bioactivity in ChEMBL (the other is dapansutrile at 1.0 μM human MDM). (In Vitro; source: nlrp3-inhibitor-screen.md)

Population context: Broad applicability for NLRP3 mechanism. No documented sex-differential effect. Mostly studied in rodent models and Chinese-medicine clinical literature; English-language clinical trial data is thin. Caution in patients on covalent-mechanism medications (irreversible MAOIs, some PPIs at high dose, omeprazole) — not a known clinical interaction but mechanistically plausible.

Dosing range: 50–100 mg/day

Form: Rabdosia rubescens extract or purified oridonin

Sourcing: - Chinese herb suppliers (Solstice Medicine, Dragon Herbs) - Research chemical suppliers (Sigma, MedChemExpress, Selleck Chem)

Contraindications: Pregnancy (insufficient data; covalent-binding mechanism warrants caution). Pediatric use. Active hepatic disease (some Rabdosia preparations have hepatotoxicity case reports at high TCM-formula doses). Combination with other covalent-mechanism drugs without spacing.

Drug interactions: - CYP3A4 substrates: preliminary in vitro data suggests modest CYP3A4 inhibition by oridonin — relevant for tacrolimus, cyclosporine, simvastatin, some calcium channel blockers, and direct oral anticoagulants. - Omeprazole, PPIs: mechanistic-extrapolation concern only; no clinical data. - Covalent-mechanism drugs (clopidogrel, prasugrel, aspirin at antiplatelet dose): theoretical compounding of covalent off-target effects; no clinical signal.

Dose-dependent risk profile: - 50–100 mg/day purified oridonin: tolerated in published TCM and supplement dosing; main risk is sourcing-quality and standardization. - 200–500 mg/day high-dose extracts: case reports of transient ALT elevation; not common but flagged. - Sourcing variability: Rabdosia rubescens whole-extract preparations contain other diterpenoids with unclear safety profiles. Purified oridonin from research chemical suppliers is more characterizable.

Stack interactions (within this catalog): - Synergy with sulforaphane, quercetin (Nrf2 axis): all three are Nrf2 activators; cumulative effect with diminishing returns. - Mechanistic complementarity with BCP, BHB, dapansutrile (CP2): oridonin (Cys279 covalent), BCP (CB2 / TLR4), BHB (K+ efflux), dapansutrile (NACHT) all suppress NLRP3 assembly through distinct molecular touch-points — orthogonal additivity expected. - No documented ABCG2 interaction.

Cost: $30–60/month

Omega-3 (High EPA / DHA)¶

Category: Fatty Acid / SPM Precursor

Mechanism: - EPA → Resolvin E1 (RvE1) - DHA → Resolvin D1/D2 (RvD1/D2), Protectin D1 (PD1), Maresin 1 (MaR1) - These specialized pro-resolving mediators (SPMs) suppress neutrophil recruitment (massive effect in gout flares), promote M1→M2 macrophage switching, and enhance efferocytosis - Hits CP1 (priming suppression) and CP5a/CP5b (IL-1β downstream effects + active resolution via ALX/FPR2) - Direct MSU gout evidence (2026-04-24): RvD1 reduced mechanical hyperalgesia, joint IL-1β, leukocyte recruitment, and ASC speck formation in murine gout (Zaninelli 2022; Animal Model); MaR1 suppressed gout inflammation via Prdx5 → AMPK/Nrf2 (Jiang 2023; Animal Model). This makes omega-3-derived SPMs among the most gout-specific compounds in the stack at CP5b. See SPM Resolution Pathway. (source: spm-resolution-pathway.md)

Evidence level: Established

Population context: Broad applicability. Pregnancy: DHA is recommended (fetal neural development); EPA-dominant formulations are less studied in pregnancy. Older adults on antiplatelet/anticoagulant therapy: bleeding-risk amplification at >3g/day combined EPA+DHA. Atrial fibrillation: high-dose (>4g/day prescription-grade) omega-3 has a modest signal of new-onset AF in recent RCTs (e.g., STRENGTH, REDUCE-IT post-hoc) — not at concern at typical 1–2g/day doses, but flagged at the upper end.

Dosing range: 3–4g EPA+DHA daily

DHA-specific update (2026-04-24 Pass 2 synthesis): The direct MSU-gout animal evidence driving this entry's CP5b ranking is DHA-derived, not EPA-derived: - RvD1 (DHA-derived) — murine MSU gout (Zaninelli 2022, PMID 35716378) - MaR1 (DHA-derived) — MSU peritonitis (Jiang 2023, PMID 37996809) - DHA separately correlates with lower circulating TNFSF14 (Huang 2024, PMID 38235898, Mendelian randomization — see tnfsf14-gout-target.md)

For gout-specific use, prefer DHA-emphasis formulations or high-DHA fish oils. EPA is not inactive (EPA → RvE1 at CP5b; EPA substrate competition reduces LTB4 at CP6a), but the specific pro-resolving and TNFSF14-suppressing signals that matter most for gout are DHA-derived. Prior "2:1 or 3:1 EPA:DHA" guidance was generalized from non-gout contexts and does not match the gout-specific data.

Form: Fish oil (DHA-emphasis preferred for gout), algae oil (often DHA-only), or krill oil

Contraindications: Severe fish/shellfish allergy (algae oil is the alternative). Active variceal bleeding. Pre-operative window (most surgeons request hold 7–14 days before procedures). Severe atrial fibrillation under aggressive rate control with high-dose (>4g/day) prescription icosapent ethyl (modest AF risk signal).

Drug interactions: - Warfarin: high-dose omega-3 (>3g/day combined) increases bleeding risk via platelet inhibition; INR may shift. Monitor and consider lower dose or hold. - Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran): additive bleeding risk at high doses; less INR-monitorable than warfarin. - Antiplatelet drugs (aspirin, clopidogrel, prasugrel, ticagrelor): additive antiplatelet effect at >3g/day. - Statins: generally synergistic on cardiovascular risk; no negative pharmacological interaction. - Antihypertensives: modest additive BP-lowering at multi-g/day omega-3.

Dose-dependent risk profile: - 1–2g/day combined EPA+DHA: well-tolerated; main effect is mild. Standard cardiovascular and dietary range. - 3–4g/day (gout-relevant range): bleeding risk becomes clinically detectable in patients on antiplatelets/anticoagulants. AF risk signal absent at this range. - >4g/day prescription-grade icosapent ethyl: documented small AF risk signal in REDUCE-IT and STRENGTH trial post-hoc analyses. Bleeding risk more pronounced. - Quality matters more than gross dose: oxidized fish oil at any dose is pro-inflammatory (peroxide value flag).

Practical note: Most consumer fish oil is heavily oxidized (damages efficacy). Use pharmaceutical-grade options: - Nordic Naturals Pro Series (molecularly distilled) - Omegaquest (clinical grade) - Or direct EPA supplementation (prescription icosapent ethyl, or OTC concentrated EPA)

Stack interactions (within this catalog): - Synergy with NAC, sulforaphane: SPM resolution layered on Nrf2/glutathione antioxidant defense. - Synergy with KPV, BPC-157 at the resolution phase (CP5): SPMs drive efferocytosis; peptides drive cytoprotection — complementary. - Caution layered with EGCG, quercetin in patients on warfarin: all three have modest antiplatelet effects; combined effect on bleeding risk is multiplicative at upper-end doses. - No documented direct ABCG2 effect. PPARγ-mediated effects of omega-3 metabolites would induce ABCG2 (per abcg2-modulators.md, PPARγ row); favorable for the gut-lumen-sink platform.

Cost: $30–50/month (quality matters)

Cherry Extract (Tart Cherry Concentrate)¶

Category: Botanical

Mechanism: Anthocyanins inhibit xanthine oxidase (direct uric acid production) and suppress CRP/IL-6; secondary anti-inflammatory

Evidence level: Supported (published pilot trials in gout; modest effect)

Population context: Broad applicability. No documented sex-differential effect. Diabetic / pre-diabetic patients should account for sugar load in cherry juice concentrate (8–12 oz can carry 30–50g sugar) — capsule form sidesteps this. Patients on tight glycemic control or low-FODMAP regimens: capsules preferred.

Dosing range: - Tart cherry juice concentrate: 8–12 oz/day (or 2–3 tbsp concentrate in water) - Dried cherry extract capsules: 500–1500 mg/day

Contraindications: None absolute. Glycemic-load concern in T2DM if using juice concentrate. Salicylate sensitivity (cherries contain natural salicylates; rare clinical relevance).

Drug interactions: - Warfarin: rare case reports of mild INR shifts at high cherry juice intakes (likely vitamin K and salicylate effects); not robust signal. - Allopurinol / febuxostat: pharmacodynamic synergy (both reduce UA via XO inhibition); generally additive rather than antagonistic, but layering may exceed XO-suppression target. - NSAIDs: mild salicylate cross-effect; clinically negligible.

Dose-dependent risk profile: - 500–1500 mg capsule extract or 8–12 oz juice/day: well-tolerated. Effect size modest (~15–20% CRP reduction). - Higher juice intakes (>16 oz/day chronic): GI upset, glycemic load. No upper-bound toxicity signal but diminishing returns past this range.

Stack interactions (within this catalog): - Synergy with quercetin, EGCG (XO axis): all three inhibit xanthine oxidase to varying degrees — additive effect on UA production. - Synergy with engineered uricase (future): XO inhibition reduces UA production; gut-lumen uricase reduces UA pool — the two mechanisms compose. - No ABCG2 interaction documented.

Cost: $20–30/month

NAC (N-Acetyl Cysteine)¶

Category: Amino Acid Precursor

Mechanism: - Replenishes glutathione (master intracellular antioxidant) - Scavenges ROS (CP2) - Targets mitochondrial dysfunction

Evidence level: Established

Population context: Broad applicability. No documented sex-differential effect. Asthma patients: NAC can transiently increase mucus secretion (mucolytic effect) — this is therapeutic in COPD/CF but can transiently worsen reactive airway symptoms in unstable asthma. Patients on nitroglycerin therapy: NAC potentiates nitrate effects (hypotension risk). Pregnancy: NAC is FDA-approved for acetaminophen overdose in pregnancy; otherwise generally regarded as safe.

Dosing range: 600–1,200 mg/day (split AM + evening)

Contraindications: Active asthma exacerbation (theoretical mucus-thinning concern; clinically minor). Pregnancy outside acetaminophen-overdose context: insufficient safety data at chronic supplement dose.

Drug interactions: - Nitroglycerin / isosorbide / nitrate-class: potentiates nitrate-induced hypotension; clinically relevant in cardiac patients. - Activated charcoal: binds NAC; spacing required if using both. - Carbamazepine: NAC may reduce serum carbamazepine levels (case-report level); monitor in epilepsy.

Dose-dependent risk profile: - 600–1200 mg/day: well-tolerated; sulfurous odor / GI upset are the practical limiters. - 1800–2400 mg/day (high-dose protocols, e.g., trichotillomania, COPD): mostly tolerated; nausea more common. - IV protocols (acetaminophen toxicity) reach much higher doses safely in supervised settings.

Stack interactions (within this catalog): - Synergy with sulforaphane, omega-3: all three activate the antioxidant defense / resolution axis (CP2 + CP5). - Mild antagonism conceptual concern: NAC's glutathione restoration could theoretically blunt some oxidative-stress-dependent signals (e.g., apoptosis induction in cancer cells); irrelevant to gout. - No ABCG2 interaction documented.

Cost: $10–15/month

EGCG (Green Tea Catechin) — Widest-Spectrum Natural Compound¶

Category: Flavonoid / Polyphenol

See wiki/egcg.md for the full dossier — proteasome → IκBα → NF-κB unifying mechanism, safety-ceiling rationale, gout-specific evidence summary, and open mechanistic questions. This entry keeps only the short stack-level summary.

Mechanism (4 of 7 chokepoints, unified through the proteasome → IκBα → NF-κB axis): - CP1 (NF-κB priming): 20S proteasome inhibition → IκBα stabilization → NF-κB blockade (IC50 = 86 nM human proteasome, ChEMBL v34, Bioorg Med Chem 2010 / Eur J Med Chem 2019). Prior "IKK inhibition" framing is downstream of / redundant with this — IKK's sole output in this pathway is to mark IκBα for proteasomal destruction, which EGCG blocks one step later. - CP1a (TNFSF14 / LIGHT direct suppression): Hosokawa 2010 (PMID 20461739) — the only stack compound with direct TNFSF14 data. Gout-relevant since TNFSF14 is an emerging gout-specific priming amplifier (see tnfsf14-gout-target.md). (In Vitro; source: nlrp3-inhibitor-screen.md) - CP4 (caspase-1 suppression): pro-caspase-1 transcription is NF-κB-dependent → same proteasome/IκBα axis blocks its induction. ROS reduction is a secondary contributor. Sub-100 nM proteasome potency is a hepatotoxicity dose-ceiling flag for intense-use protocols. - CP5a (IL-1β receptor-downstream suppression): same proteasome/IκBα axis on receiving cells (chondrocytes, synoviocytes) blocks IL-1β-induced NF-κB signaling.

Evidence level (PROMOTED to Tier 2 supplement use, 2026-04-23 re-audit): Direct MSU mouse gout evidence — Lee 2019 Molecules (PMID 31174271): EGCG blocked MSU-induced caspase-1(p10) and IL-1β in primary mouse macrophages; oral EGCG alleviated MSU-injected mouse foot inflammation via NLRP3 suppression; mechanism = mtDNA synthesis block + ROS reduction. Plus hyperuricemic mouse serum-UA lowering (Yu 2024, Food Funct, PMID 38757391). The prior "no gout evidence" framing missed these. (Animal Model; source: nlrp3-inhibitor-screen.md)

Population context: Broad applicability for NLRP3 mechanism, but functional ABCG2 inhibitor at supplement doses — relevant for the engineered-uricase platform. Yu 2024 mouse data shows favorable in vivo phenotype on urate axis in hyperuricemic mice despite EGCG's known in vitro BCRP inhibition; net clinical effect on the gut sink in androgen-dominant patients is unresolved (see Stack-level contradictions section). Hepatotoxicity risk is dose-dependent and sex-irrelevant but amplified by alcohol, fasting, pre-existing liver disease, and male androgen-axis liver-stress patterns. Avoid in pregnancy at supplement (>500 mg/day) doses; food-level intake (matcha, green tea) is acceptable.

Dosing range: 400–800 mg EGCG/day (standardized green tea extract) OR 3–5 cups matcha/day

Form: Standardized green tea extract (typically 50% EGCG) OR matcha powder (highest natural concentration)

Contraindications: Active hepatic disease or recent ALT/AST elevation. Pregnancy at supplement doses (folate antagonism + theoretical hepatotoxicity). Concurrent alcohol use disorder or chronic high alcohol intake (additive hepatotoxicity). Iron-deficiency anemia (EGCG strongly chelates non-heme iron — separate iron supplementation by 2+ hours from EGCG).

Drug interactions: - Warfarin: EGCG may modestly antagonize warfarin (vitamin K-like effect from green tea has been reported; effect is small but can shift INR). - Bortezomib (proteasome inhibitor chemotherapy): EGCG directly binds and inactivates bortezomib; avoid coadministration in oncology patients on bortezomib. - Beta-blockers (nadolol): EGCG reduces nadolol oral bioavailability via OATP1A2 inhibition; clinically significant. - Hepatotoxic drugs (acetaminophen, isoniazid, methotrexate, statins): additive hepatotoxicity risk at high EGCG doses. - Iron supplements: chelation; separate dosing. - CYP3A4 substrates (modest): in vitro inhibition; clinically modest.

Dose-dependent risk profile: - 200–400 mg/day EGCG (standardized extract): well-tolerated; comparable to heavy daily green tea drinker. - 400–800 mg/day (gout-relevant range): hepatotoxicity risk becomes detectable, especially under fasting conditions or with alcohol. Periodic ALT/AST monitoring recommended. - >800 mg/day: case reports of serum hepatitis (idiosyncratic, low absolute incidence). Hard ceiling for chronic intense use. - Matcha-based dosing (food matrix) appears safer at equivalent EGCG content than capsule extracts — likely due to slower absorption and matrix-buffered exposure.

Hepatotoxicity dose ceiling: The 86 nM 20S proteasome IC50 is a safety flag at high-dose intense use. Stay at or below 800 mg EGCG/day; avoid combining high-dose EGCG with alcohol or other hepatotoxic agents; consider periodic ALT/AST monitoring at sustained high doses.

Stack interactions (within this catalog): - Stack contradiction (ABCG2 axis): EGCG is a functional ABCG2 inhibitor (Tier 2 contradiction; see Stack-level contradictions table at bottom and abcg2-modulators.md). Yu 2024 (PMID 38757391) shows net-favorable effect on ABCG2/URAT1/GLUT9 in vivo in hyperuricemic mice — direction opposite to in vitro inhibition — so net effect on the gut sink in androgen-dominant patients is unresolved. Avoid layering EGCG with curcumin, quercetin, genistein in high-T or Q141K-positive patients until the in vivo question is resolved. - Synergy with quercetin, sulforaphane (NF-κB / Nrf2 axis): mechanistically compatible at the NLRP3 priming level. - Hepatotoxic stacking concern: EGCG + high-dose curcumin + acetaminophen / alcohol creates a multiplicative liver-stress profile. Stagger or substitute.

Summary framing: EGCG is the widest-spectrum natural compound in the current Open Enzyme stack, hitting four of seven chokepoints. Its 20S proteasome sub-100 nM activity is a hepatotoxicity flag at high dose — safety dose-ceiling for intense use protocols.

⚠️ ABCG2 functional inhibitor warning (source: abcg2-modulators.md): EGCG is a documented functional ABCG2/BCRP inhibitor in pharmacology assays. Yu et al. 2024 (Food Funct, PMID 38757391) showed a net-favorable effect on ABCG2/URAT1/GLUT9 expression at the tissue level in a hyperuricemic mouse model — direction opposite to the in vitro inhibition story. Net clinical effect on the gut urate sink is unresolved. Until resolved, treat high-dose EGCG (>400 mg/day) as a potential ABCG2 inhibitor in the gut-lumen context, particularly in androgen-dominant or Q141K-positive patients. (Mixed: In Vitro inhibition vs. Animal Model in vivo; source: abcg2-modulators.md)

Cost: $15–25/month (standardized extract); $30–50/month (high-grade matcha)

Limonene (d-Limonene, Citrus Peel Oil) — PROMOTED Tier 3 Supplement¶

Category: Monoterpene / Food Additive (GRAS)

Mechanism: Nrf2 activator + TLR4 suppression (upstream NLRP3 priming block); also suppresses NF-κB, NLRP3, ASC, caspase-1 expression via NRF2-dependent pathway.

Evidence level (PROMOTED to Tier 3 supplement, 2026-04-23 re-audit): Direct rat PO+MSU dual gout model — Venkatesan 2025 Nutrients (PMID 41515190): 50 mg/kg limonene reduced paw thickness, serum UA, IL-1β/TNF/IL-6, and improved antioxidant status; authors invoke NLRP3-IL-1β suppression as the mechanistic frame. (Animal Model; source: nlrp3-inhibitor-screen.md)

Population context: Broad applicability. No documented sex-differential effect. GERD patients: d-limonene is actually marketed for GERD support, but at the same dose can transiently worsen reflux in subset (paradoxical effect from LES relaxation in some). Pregnancy: insufficient supplement-dose data; food-level intake fine.

Dosing range: 500–1,000 mg d-limonene/day (standardized capsules). Supplement capsule is the practical path — engineered microbial production is infeasible (<20 mg/L titers + volatility).

Form: d-limonene softgel capsules (commonly sold for GERD / digestive support)

Contraindications: None absolute. Citrus allergy (rare; d-limonene is the dominant terpene in citrus peel).

Drug interactions: - CYP3A4 substrates (statins, calcium channel blockers, immunosuppressants): d-limonene weakly induces CYP3A4 at chronic doses; clinical significance is small at the gout-relevant range. - Acid-suppression drugs (PPIs, H2 blockers): mechanistic overlap with GERD use; not a pharmacological conflict.

Dose-dependent risk profile: - 500–1,000 mg/day: well-tolerated. GRAS food-additive compound at much higher cumulative dietary exposure (orange peel, citrus oils in foods). - >2 g/day chronic: case reports of mild hepatic enzyme elevation (rare; idiosyncratic). - Inhalation/vaporized forms have very different PK and are not appropriate for NLRP3/gout endpoint use.

Stack interactions (within this catalog): - Synergy with sulforaphane, oridonin (Nrf2 axis): cumulative Nrf2 induction with diminishing returns. - No ABCG2 interaction documented.

Cost: $15–25/month

Lactoferrin (Bovine) — NEW CP5 Entry¶

Category: Glycoprotein / Food-Grade Supplement

Mechanism (CP5 — the one CP5-active entry in the stack that isn't a $300K/year biologic): - NLRP3 / caspase-1 / GSDMD axis suppression → reduces IL-1β and IL-18 output - Orthogonal to polyphenol CP1 mechanisms and direct NLRP3 binders (CP2) - Talactoferrin (recombinant human lactoferrin, ChEMBL2108651) reached Phase 3 oncology at multi-g/day oral doses — safety and oral bioavailability established

Evidence level: Animal (murine nephrotoxicity, PMID 37926296 — 300 mg/kg/day back-translates to ~3 g/day human); In Vitro (macrophages + IEC-6 intestinal epithelial cells); Clinical Phase 3 (talactoferrin oncology). Direct MSU-gout validation not yet published — CP5 mechanism is the gout-relevant class; priority experimental screen. (Animal Model + Clinical Trial; source: nlrp3-inhibitor-screen.md)

Population context: Broad applicability. No documented sex-differential effect. Iron-related considerations: lactoferrin is iron-binding but bovine lactoferrin in supplement form is largely iron-saturated (apo-lactoferrin vs holo-lactoferrin distinction matters mechanistically). Patients with hemochromatosis: theoretical iron-loading concern with high-dose holo-lactoferrin; minor clinically. Bovine milk allergy: cross-reactive risk (lactoferrin is a milk protein).

Dosing range: - Commercial oral bovine lactoferrin: 100–300 mg/day (typical capsule) - Murine protective dose (300 mg/kg/day) back-translates to ~3 g/day human — achievable at engineered P. pastoris fermentation scale (3.5 g/L demonstrated, PMID 27294912)

Form: Bovine colostrum-derived capsules (commercial supplement); future: engineered P. pastoris or koji (A. oryzae) recombinant production

Contraindications: Bovine milk allergy. Hemochromatosis (relative; high-dose chronic only). Pregnancy: dietary lactoferrin from colostrum is generally regarded as safe; supplement-dose chronic is less characterized.

Drug interactions: - Iron supplements: lactoferrin can compete with or chelate iron depending on its iron-saturation state; spacing recommended. - Antibiotics (tetracyclines, fluoroquinolones): theoretical chelation via lactoferrin's iron-binding sites; minor clinical relevance, separate dosing if both prescribed simultaneously. - No major small-molecule pharmacological interactions documented.

Dose-dependent risk profile: - 100–300 mg/day (commercial capsule range): well-tolerated. - 1–3 g/day (talactoferrin Phase 3 range): tolerated in oncology populations; GI symptoms most common. - Bridge between commercial and trial doses (300 mg → 3 g) is the practical scale-up question for the platform.

Stack interactions (within this catalog): - Mechanism orthogonality (the strategic position): lactoferrin is the only CP5-active stack compound that is not a $300K/year biologic (canakinumab) — fills a unique position. Mechanism does not overlap with polyphenol NF-κB/Nrf2 cluster. - No ABCG2 interaction documented.

Strategic position: The only CP5 candidate in the stack that is fermentable at scale, food-grade, and has direct NLRP3/IL-1β evidence. Fills the Open Enzyme CP5 gap that canakinumab currently occupies at ~$300K/year. Koji expression not yet tried — potential future module for the Open Enzyme platform.

Cost: $30–60/month (bovine oral capsules, 300 mg/day)

Carnosine (L-Carnosine, β-Alanyl-L-Histidine) — Dual UA + NLRP3¶

Category: Dipeptide / Endogenous Muscle Metabolite

Mechanism (unique dual phenotype: serum UA reduction + NLRP3 suppression in same compound): - ROS scavenging, p-p65 (NF-κB) suppression, p-JNK dampening - Direct NLRP3, caspase-1 suppression (downstream of ROS / NF-κB block) - URAT1 and GLUT9 transporter modulation → enhanced renal urate excretion

Evidence level: Animal Model (hyperuricemia rat) — carnosine reduces serum uric acid AND suppresses NLRP3 inflammasome activation simultaneously; the only compound in the stack with this documented dual phenotype. (Amino Acids 2024; see nlrp3-inhibitor-screen.md for full citation trail.)

Population context: Broad applicability with specific relevance to androgen-driven hyperuricemia. Carnosine's URAT1 modulation is mechanistically aligned with reversing the androgen-driven URAT1 upregulation documented in androgen-urate-axis.md — making carnosine particularly well-suited for male gout patients on TRT, SERMs, or with high endogenous T. Vegetarians/vegans: dietary carnosine intake is essentially zero from plant foods; supplementation produces a larger relative shift.

Dosing range: 500–1,000 mg/day oral L-carnosine (split doses preferred; dipeptide transporter-mediated absorption)

Form: L-carnosine capsules (widely available); avoid carnosine analogs (anserine, balenine) unless specified

Contraindications: None absolute. Pregnancy: insufficient supplement-dose data; dietary intake from meat fine.

Drug interactions: Minimal documented interactions. Mechanistically: - ACE inhibitors: carnosine is endogenously degraded by serum carnosinase; ACE inhibitors are unrelated. - Histidine-axis drugs (rare): clinically negligible.

Dose-dependent risk profile: - 500–1,000 mg/day: well-tolerated. Serum carnosinase rapidly degrades free carnosine, so plasma levels are transient — practical absorption ceiling. - Higher doses produce diminishing returns due to carnosinase saturation; β-alanine supplementation is a precursor strategy that bypasses some of this but produces tingling (paresthesia) at therapeutic doses.

Stack interactions (within this catalog): - Strong synergy with engineered-uricase platform (mechanism-orthogonal): carnosine reduces UA via URAT1/GLUT9 (renal) modulation; engineered uricase reduces UA via gut-lumen sink. Two non-overlapping mechanisms — additive expected. - Synergy in androgen-driven hyperuricemia: counters URAT1 upregulation that exogenous T / SERMs / AAS produce. - No ABCG2 interaction documented. Does not antagonize the platform.

Strategic position: Unique dual-phenotype (UA + NLRP3) that other stack compounds don't match. ~150 mg/L estimated titer in engineered yeast — moderate engineering complexity, lower titer than polyphenols, but the only compound that compresses both problems (hyperuricemia + inflammasome) into a single molecule. Co-engineering with uricase in koji is the long-term platform play.

Cost: $20–35/month (oral L-carnosine, 500–1,000 mg/day)

Tongkat Ali (Eurycoma longifolia — Physta / LJ100) — Dual T-axis + UA-Favorable¶

Category: Herbal / SHBG Modulator / Multi-Target Urate Modulator

Mechanism (dual phenotype: free-T elevation + serum UA reduction — rare in the T-axis adjuvant class): - SHBG displacement — quassinoid metabolites (eurycomanone) compete with testosterone for SHBG binding, freeing bound T into the active free fraction. Meta-analysis (Leisegang 2022, PMID 36013514): pooled SMD = 1.352, p = 0.001 for total T elevation; significant in hypogonadism subgroup, non-significant in eugonadal men. (Clinical Trial) - Multi-target urate modulation — eurycomanone and eurycomanol downregulate URAT1 + GLUT9, upregulate ABCG2 + NPT1 in kidney (PMID 31920654, Animal Model); eurycomanol suppresses PRPS-driven purine biosynthesis (PMID 34785103, In Vitro) — see prps-purine-biosynthesis-chokepoint.md. Tongkat ali is NOT an XO inhibitor — the supplement-industry "XO inhibition" claim is a citation-laundering artifact; the actual mechanism is multi-target transporter modulation + purine-synthesis suppression. (Animal Model + In Vitro; source: t-axis-adjuvant-urate-mapping-computational.md) - Human UA-lowering RCT: 2021 placebo-controlled trial (n=105 men aged 50–70, Physta 100/200 mg/d × 12 wk): SUA ↓7% at 100 mg/d, ↓11% at 200 mg/d. (Clinical Trial; source: androgen-natural-modulation.md §1.7)

Evidence level: Clinical Trial (T elevation meta-analysis + UA-lowering RCT) + Animal Model (urate transporter modulation) + In Vitro (PRPS suppression)

Population context: Best-evidenced herbal T-axis adjuvant for the gout-comorbid case. The dual T-up + UA-down phenotype is rare — most T-elevation interventions raise UA via URAT1. Particularly relevant for men with mild hypogonadism + gout who want T-axis support without worsening hyperuricemia. Effect on T is modest (10–30% free-T elevation in mildly suboptimal men, near-zero in already-eugonadal men per Leisegang 2022). Not a replacement for clomiphene at full pharmacological dose in true secondary hypogonadism. (source: androgen-natural-modulation.md)

Dosing range: - Physta (Biotropics Malaysia, hot-water extract): 200 mg/day — the most-RCT-validated extract; standardized to 0.8–1.5% eurycomanone - LJ100 (HP Ingredients): 200 mg/day — different extraction protocol; smaller clinical corpus - Avoid unstandardized "100:1" or "200:1" bulk extracts — ratio nomenclature is meaningless without quassinoid assay

Contraindications: Pregnancy (insufficient data). Active hepatic disease (theoretical quassinoid hepatic stress at supplemented doses — not clinically documented). Insomnia / increased aggression are the most-reported subjective side effects (consistent with raised free-T).

Drug interactions: - CYP3A4 substrates: mild in vitro inhibition by quassinoids; clinical significance small at standard doses. - Warfarin / antiplatelets: no documented interaction. - SERMs (clomiphene, tamoxifen): additive T-elevation — monitor free-T and UA if combining.

Dose-dependent risk profile: - 200 mg/day standardized Physta or LJ100: well-tolerated; the RCT-validated dose. - 400 mg/day: some studies show no advantage over 200 mg (saturation). Dose-stacking above 400 mg has no RCT support. - Heavy-metal contamination risk in non-standardized Indonesian product — standardized Physta or LJ100 from reputable supplier only.

Stack interactions (within this catalog): - Cordyceps (additive, not redundant): both are gout-favorable T-axis adjuvants via different mechanisms — cordycepin (URAT1-dominant), eurycomanone (multi-target transporter + PRPS). Mechanism-orthogonal; stacking is supported. See t-axis-adjuvant-urate-mapping-computational.md for the head-to-head analysis. (source: t-axis-adjuvant-urate-mapping-computational.md) - Carnosine (overlap at URAT1): both downregulate URAT1 — diminishing returns if stacked at maximum dose; pick one for the URAT1 axis. - No ABCG2 interaction documented. Tongkat ali is NOT on the curcumin/quercetin/EGCG/genistein ABCG2 functional-inhibitor list. Favorable for the gut-lumen-sink platform. - Synergy with engineered uricase (future): tongkat ali's multi-target transporter modulation (URAT1↓, ABCG2↑) opens both the renal and intestinal urate-handling gates — complementary to gut-lumen uricase degradation.

Cost: $25–50/month (standardized Physta or LJ100, 200 mg/day)

Reference: androgen-natural-modulation.md §1 for the full entry including RCT effect sizes, standardization details, and the UA-direction reversal finding (2026-05-07).

Quercetin (Phytosome Form Preferred)¶

Category: Flavonoid

Mechanism (reordered 2026-04-24 by dominant curated activity): - PRIMARY — 5-lipoxygenase (5-LOX) inhibition, IC50 = 300 nM (CP6a) — blocks leukotriene B4 (LTB4) production, suppressing the neutrophil chemotaxis that amplifies MSU-driven gout flares. This is quercetin's single most potent curated ChEMBL bioactivity (J Med Chem 1991, ChEMBL v34, 2026-04-23). More potent than its NF-κB/NLRP3-pathway IC50 (~11 μM functional) by ~36×. Quercetin is now framed primarily as a CP6a compound on the exploit map. (In Vitro; source: nlrp3-inhibitor-screen.md) - SECONDARY — NF-κB inhibition (CP1) — NLRP3 pathway modulator via NF-κB priming block (not direct NLRP3 binding; zero curated human NLRP3 IC50 in ChEMBL) - TERTIARY — Xanthine oxidase inhibition — direct uric acid production reduction (metabolic / upstream of MSU crystal formation) - Mast cell stabilization

⚠️ ABCG2 functional inhibitor warning (source: abcg2-modulators.md): Quercetin is a competitive substrate/inhibitor of ABCG2 at low μM gut-lumen concentrations — the same range achieved at supplement doses (500–1,000 mg/day). This means quercetin may acutely suppress intestinal urate secretion, pharmacologically antagonizing the gut-lumen-sink thesis. The net effect is dose-dependent and context-dependent: chronic low-dose dietary quercetin may show transcriptional upregulation of ABCG2 in some animal studies, but supplement-grade acute dosing is the concern. For male gout patients on TRT, SERMs, or with Q141K polymorphism — where ABCG2 is already suppressed — high-dose quercetin supplementation may compound the deficit. (In Vitro; source: abcg2-modulators.md)

Evidence level: In Vitro 300 nM 5-LOX IC50 per ChEMBL; Established (NF-κB + xanthine oxidase)

Labeling note: Quercetin has zero curated direct human NLRP3 bioactivities in ChEMBL — it is more accurately an "NLRP3 pathway modulator" (NF-κB priming block) than a direct NLRP3 binder. The gout-relevant case rests on three orthogonal mechanisms: NF-κB priming block, xanthine oxidase inhibition, and 5-LOX/LTB4 block. (source: nlrp3-inhibitor-screen.md)

Population context: Broad applicability for NLRP3/XO mechanism, but functional ABCG2 inhibitor at typical supplement doses (Stack-level contradiction; see bottom section and abcg2-modulators.md). Particularly relevant for male gout patients on TRT/SERMs/AAS or Q141K-positive patients where the gut-lumen-sink is already androgen-suppressed — high-dose quercetin may further close the leaky-gate. Pregnancy: limited supplement-dose data; dietary intake from onions, apples, capers is fine.

Dosing range: 500–1,000 mg/day

Form: Phytosome (Quercefit) has ~20× better absorption than standard quercetin

Contraindications: None absolute. Patients on tight CYP3A4-substrate dosing (cyclosporine, tacrolimus) should be cautious at high-dose quercetin. Pregnancy: insufficient supplement-dose data.

Drug interactions: - CYP3A4 substrates (cyclosporine, tacrolimus, simvastatin, calcium channel blockers): quercetin inhibits CYP3A4 in vitro at supplement-relevant gut concentrations; clinically detectable drug-level increases possible. - Warfarin: modest antiplatelet/anticoagulant effect; INR may shift. - Quinolone antibiotics (ciprofloxacin, levofloxacin): quercetin chelates and reduces absorption; separate dosing. - Allopurinol: quercetin's XO inhibition is mechanistically additive — not necessarily problematic, but UA may drop more than expected when both are dosed together.

Dose-dependent risk profile: - 250–500 mg/day standard quercetin or phytosome equivalent: well-tolerated; dietary range upper end. - 500–1,000 mg/day (gout-relevant range): well-tolerated; CYP3A4 inhibition becomes clinically detectable. - 1,500–2,000 mg/day chronic: rare nephrotoxicity case reports at very high doses; unlikely at the gout-relevant range.

Practical note: Triple mechanism: hits CP1 (priming), uric acid production (xanthine oxidase), AND neutrophil chemotaxis (5-LOX/LTB4). The 5-LOX leg is parallel to boswellic acids (AKBA) at the same target. Synergizes with sulforaphane (both Nrf2 activators). (Source: nlrp3-exploit-map.md)

Stack interactions (within this catalog): - Stack contradiction (ABCG2 axis): quercetin is a functional ABCG2 inhibitor at low-μM gut concentrations — Tier 2 contradiction in the Stack-level contradictions table at bottom. Per abcg2-modulators.md, chronic dosing also produces some transcriptional ABCG2 upregulation in animal studies — net effect on the gut-lumen sink is dose- and duration-dependent and poorly characterized in humans. Acutely (peak gut concentration after a high-dose phytosome), the inhibitory effect dominates. - Synergy with sulforaphane, oridonin (Nrf2 axis): Nrf2 cluster. - Synergy with cherry extract (XO axis): overlapping XO inhibition; additive UA reduction. - Caution with EGCG, curcumin, genistein: all four are functional ABCG2 inhibitors — stacking them concentrates the gut-sink antagonism in androgen-dominant readers.

Cost: $15–25/month

Beta-Caryophyllene (Black Pepper / Clove Extract)¶

Category: Sesquiterpene / CB2 Agonist / Food Additive (GRAS)

Mechanism: Selective CB2 receptor agonist (Ki ~155 nM; CB2-over-CB1 selectivity >100×). In MSU-induced gouty arthritis (rat, animal model), 100–400 mg/kg oral dose-dependently reduced ankle swelling, serum IL-1β/IL-6/TNF-α, and synovial NLRP3/caspase-1/ASC/TLR4/MyD88/NF-κB expression — hits CP1 (NF-κB via TLR4/MyD88) AND CP2 (NLRP3/caspase-1). Mechanistically distinct from oridonin (Cys279) or BHB (K⁺ efflux) — additive potential. (Front Pharmacol 2021;12:651305, PMID: 33967792.) (source: cannabinoids-terpenes.md)

Evidence level: Animal Model (MSU crystal rat gouty arthritis — the only cannabinoid or terpene with direct gout-model data)

Population context: Broad applicability. No documented sex-differential effect. CB2-selective mechanism avoids the CB1-mediated gut motility slowdown that would be a concern in EPI patients (relevant given the Open Enzyme dual-target focus). GRAS food additive; non-psychoactive.

Dosing range: - Standardized beta-caryophyllene (BCP) supplement: 50–200 mg/day (available as copaiba oil extract, 45–55% BCP standardization) - Dietary: Black pepper, clove, hops, copaiba — dietary intake typically <10 mg/day from food alone

Dose-translation caveat (flagged 2026-04-23, see synthesis/ (architecture: synthesis/README.md)): The 2021 MSU rat gout efficacy was demonstrated at 100–400 mg/kg oral. BSA-scaled to a 70 kg human, that is ~1.1–4.5 g/day — 20–50× above the typical supplement dose listed above. Whether 50–200 mg/day reproduces the synovial NLRP3/TLR4/NF-κB suppression seen in rats is unverified. Treat this entry as "plausible mechanism, dose adequacy unconfirmed" until a PK/PD translation check or human bioavailability study resolves the gap. The orthogonal CB2 mechanism still makes BCP a reasonable low-risk addition; just do not assume the rat dose-response translates to supplement-range doses.

Contraindications: None absolute. Pregnancy: dietary spice exposure is fine; supplement-dose chronic is unstudied.

Drug interactions: - CB2-targeted experimental drugs: competitive at CB2; not clinically relevant outside research settings. - CYP2C9, CYP3A4 substrates: mild in vitro inhibition; clinical relevance small at supplement doses. - Cannabinoid-class drugs (dronabinol, nabilone): mechanism overlap (different receptor selectivity); no clear clinical conflict.

Dose-dependent risk profile: - 50–200 mg/day BCP capsules: well-tolerated; food-additive level cumulative exposure. - Higher doses up to 1 g/day in animal studies: tolerated; no hepatotoxicity signal. - Inhalation/vaporized cannabis terpene products have very different PK and are not equivalent to oral BCP capsules for this endpoint.

Practical note: Non-psychoactive, not cannabis-derived (present in many food spices). GRAS food additive. Not a CB1 agonist — avoids the THC regulatory/psychoactivity concerns and the CB1-mediated gut-motility slowdown that would be a risk in EPI. (source: cannabinoids-terpenes.md)

Stack interactions (within this catalog): - Mechanism orthogonality (CP2): distinct molecular touch-point from oridonin (Cys279), BHB (K+ efflux), dapansutrile (NACHT) — additive at the NLRP3-assembly level. - No ABCG2 interaction documented.

Cost: $15–30/month (BCP-standardized copaiba capsules)

Vitamin D3 + K2¶

Category: Fat-Soluble Vitamin

Mechanism: VDR activation suppresses NF-κB (CP1); K2 prevents vascular calcification (secondary benefit)

Evidence level: Established

Population context: Broad applicability with population-specific dosing. Sun-exposed individuals at temperate latitudes often need less; high-latitude / dark-skinned / indoor-occupation individuals need more. Pregnancy: D3 supplementation routinely recommended (2000–4000 IU). Patients with sarcoidosis, primary hyperparathyroidism, or granulomatous diseases: D3 supplementation can cause hypercalcemia and is contraindicated without specialist supervision. Patients on warfarin: K2 directly antagonizes warfarin effect and requires INR monitoring or dose adjustment.

Dosing range: - Vitamin D3: 5,000–10,000 IU/day (target serum 50–70 ng/mL; test annually) - K2 (MK-7): 200 mcg/day

Contraindications: Sarcoidosis or granulomatous disease (D3-driven hypercalcemia risk). Primary hyperparathyroidism. Hypercalcemia of any cause. K2: warfarin therapy is a relative contraindication — K2 directly antagonizes warfarin and requires INR re-stabilization or dose adjustment.

Drug interactions: - Warfarin: K2 directly antagonizes warfarin via vitamin K-cycle competition; clinically significant. Requires INR monitoring with consistent K2 dosing or dose adjustment. - Thiazide diuretics: D3-driven calcium retention is amplified; hypercalcemia risk. - Glucocorticoids: can reduce D3 efficacy on bone via competing pathways. - Statins: generally favorable interaction (D3 may modestly improve statin tolerance via myopathy risk reduction). - Anticonvulsants (phenytoin, phenobarbital, carbamazepine): induce CYP24A1, accelerating D3 catabolism; higher D3 doses may be needed.

Dose-dependent risk profile: - 1,000–4,000 IU/day D3: standard supplemental range; minimal hypercalcemia risk. - 5,000–10,000 IU/day (gout-relevant range): track 25-OH-D level annually; target 50–70 ng/mL. Hypercalcemia rare in non-granulomatous patients at this range. - >10,000 IU/day chronic: hypercalcemia risk becomes detectable; serum monitoring (Ca, 25-OH-D, PTH) recommended. - K2 200 mcg/day: well-tolerated; no toxicity ceiling identified at typical supplement doses.

Practical note: Must be taken with fat to absorb

Stack interactions (within this catalog): - No major stack interactions. D3 is mechanistically synergistic at the broad NF-κB suppression level but operates on its own axis (VDR). - No ABCG2 interaction documented.

Cost: $10–15/month

Section 2: SOON (Implementation Within 2-4 Weeks)¶

Compounds and approaches that are viable near-term but require medical discussion or sourcing from specialty suppliers.

Disulfiram (Antabuse)¶

Category: Approved Drug / GSDMD Inhibitor

Mechanism: Covalently modifies Cys191 on gasdermin D → blocks pore formation (CP6). Allows IL-1β cleavage but prevents pyroptosis and cell rupture.

Evidence level: Established (Nature Immunology 2020; works at nanomolar concentrations in humans)

Population context: Broad applicability for GSDMD mechanism, but the absolute alcohol contraindication is the dominant population filter. Patients who consume alcohol in any form (including some mouthwashes, OTC cold preparations, kombucha, or fermented foods with residual ethanol) cannot use disulfiram safely. Patients with hepatic dysfunction: dose-reduced or contraindicated. Pregnancy: contraindicated. Older adults: increased CNS side effects.

Dosing range: 250 mg once daily (standard for alcohol use disorder; off-label for gout). Sub-AUD GSDMD-dominant window per comp-027 (2026-05-16, YELLOW-leaning-GREEN): 100 mg/day (range 75–125 mg/d) — at this dose, parent DSF Cmax (0.40 µM) engages GSDMD pore-formation blockade at 1.3× cell-free IC50 while plasma Me-DTC peak (~70 nM) stays at or below the DER hypotension threshold. Two-phase compounding protocol: IR capsule 50→100 mg/d titration over 14 days, then ER lipid-matrix 100 mg QD chronic. (Mechanistic Extrapolation + In Silico; source: disulfiram-dose-modeling-computational.md)

Key advantage: FDA-approved for 70+ years, well-tolerated in alcohol-abstinent patients, ~$30/month

Contraindications: Any alcohol use (acute disulfiram-ethanol reaction: flushing, tachycardia, hypotension, severe nausea — can be fatal at high alcohol doses). Active hepatic disease (LFTs >3× upper limit of normal). Severe coronary artery disease (cardiovascular collapse risk on ethanol exposure). Severe psychosis (case reports of psychotic exacerbation). Pregnancy. Concurrent metronidazole or other disulfiram-like agents.

Drug interactions: - Metronidazole, tinidazole, cefoperazone, griseofulvin, certain MAOIs, isoniazid: disulfiram-like reactions amplified. - Warfarin: disulfiram inhibits warfarin metabolism → increased anticoagulation; INR monitoring required. - Phenytoin: disulfiram inhibits phenytoin metabolism → toxicity risk. - Theophylline, caffeine (high-dose): disulfiram inhibits clearance; toxicity risk. - Benzodiazepines metabolized by CYP3A4 (alprazolam, midazolam): disulfiram inhibits clearance; sedation risk. - Acetaminophen at high doses: competing hepatic stress (additive hepatotoxicity). - Many ethanol-containing medications (some elixirs, sublingual sprays, IV preparations): trigger reaction.

Dose-dependent risk profile: - 250 mg/day (standard): well-tolerated in alcohol-abstinent patients. Hepatotoxicity (idiosyncratic) is the main rare serious side effect; baseline + periodic LFTs recommended. - 500 mg/day (historical dose, less common now): more side effects (drowsiness, peripheral neuropathy, hepatic stress) without proportional efficacy gain. - Disulfiram-ethanol reaction severity scales with both disulfiram dose and ethanol exposure.

Medical requirement: Requires physician discussion. Can frame as off-label GSDMD inhibitor for gout flare prevention, or as standard-of-care for any alcohol use history.

Practical note: This is the single most accessible pharma-grade NLRP3 pathway exploit in the entire supplement arsenal. (Source: nlrp3-exploit-map.md)

Stack interactions (within this catalog): - Mechanism orthogonality (CP6): distinct CP from any other stack compound — covers pyroptosis pore-formation specifically. - Hepatotoxicity stacking concern with EGCG, high-dose curcumin, acetaminophen: all four contribute to hepatic stress; layering is a relative contraindication. - Caution with fermented foods: kombucha and some koji preparations may contain residual ethanol that could trigger reaction in disulfiram-sensitive patients. Practical limit: dietary intake of well-fermented foods at typical portion sizes is generally below the threshold but is patient-specific. - No ABCG2 interaction documented.

Cost: ~$30/month

Tranilast¶

Category: Approved Drug (Japan/Korea) / NLRP3 Inhibitor

Mechanism: Direct NACHT domain binder; blocks NLRP3 oligomerization via different mode than MCC950/oridonin

Evidence level: Established (EMBO Molecular Medicine: "remarkable preventive or therapeutic effects" on gouty arthritis, CAPS, type 2 diabetes)

Population context: Broad applicability for NLRP3 mechanism. Approved in Japan (Rizaben) and South Korea since 1982; not FDA-approved in US. International sourcing introduces supply-quality variability. Pregnancy: insufficient data for off-label indication.

Dosing range: 300–600 mg/day

Access: Approved in Japan (Rizaben) and South Korea since 1982; not FDA-approved in US but available through: - International pharmacies - Informed physician compassionate use - Clinical trial if enrolled (unlikely for gout specifically)

Safety profile: Up to 600 mg/day used clinically for months without hepatotoxicity (unlike MCC950)

Contraindications: Pregnancy (insufficient gout-indication data, though approved in pregnancy for keloid prevention in Japan with documented safety). Severe hepatic or renal disease.

Drug interactions: - Warfarin: modest interaction reported in Japanese post-marketing data; INR monitoring at initiation. - Loop diuretics: mild renal interaction at high tranilast doses. - No major CYP-mediated clinical interactions documented at standard doses.

Dose-dependent risk profile: - 300–600 mg/day: well-tolerated chronically (decades of post-marketing data). - Higher doses (>600 mg/day): rare bladder symptoms, hepatic enzyme elevation; not the gout-relevant range.

Medical requirement: Requires physician discussion; insurance unlikely to cover off-label, may be out-of-pocket

Stack interactions (within this catalog): - Mechanism orthogonality (CP2 NACHT): distinct binding mode from oridonin (Cys279); could be additive. - No ABCG2 interaction documented.

Cost: $50–100/month (international shipping)

Fermented Foods (Spermidine & Trehalose Boost)¶

Category: Dietary

Mechanism: - Spermidine induces autophagy (CP2/CP3 target); direct NLRP3 suppression - Trehalose activates TFEB → autophagy via mTOR-independent pathway - Both compounds suppress NLRP3 accumulation

Evidence level: Established

Population context: Broad applicability with diet-specific considerations. Histamine-intolerant patients: aged cheese, natto, kimchi, kombucha all carry significant histamine load; may not tolerate. Disulfiram users: kombucha and koji-fermented foods may carry residual ethanol triggering reaction. SIBO patients: fermented foods with live cultures may transiently worsen symptoms before improving.

Foods: - Spermidine-rich: Aged cheese (Parmesan, cheddar), natto (fermented soy), mushrooms, wheat germ - Trehalose-rich: Mushrooms, honey, shrimp

Dosing range: - Spermidine supplement: 1–6 mg/day, but food sources preferred - Natto: 1–2 servings/week provides ~70 nmol/g (one of richest sources) - Trehalose: 5–10g/day in water or added to beverages

Contraindications: Histamine intolerance (aged/fermented foods). Disulfiram therapy (residual ethanol concern in kombucha specifically). Severe immunocompromise (live-culture fermented foods may carry small infection risk).

Drug interactions: - Warfarin: natto is exceptionally high in vitamin K2 — directly antagonizes warfarin and requires either consistent intake with INR adjustment, or avoidance. - MAOIs: aged cheese and some fermented foods carry tyramine load; hypertensive crisis risk with MAOIs. - Disulfiram: see above (residual ethanol).

Dose-dependent risk profile: - Dietary fermented foods at normal portion sizes: well-tolerated. - High-dose spermidine supplements (>6 mg/day): under-characterized; some animal data suggests longevity benefits but human data is thin. - Trehalose >20g/day: GI upset (osmotic).

Stack interactions (within this catalog): - Synergy with intermittent fasting (autophagy axis): both push TFEB/autophagy — additive. - Synergy with omega-3 (resolution-phase): SPMs + autophagy = clearance and resolution. - Soy-derived fermented foods (miso, natto, tempeh) carry genistein and daidzein — small but measurable amounts of ABCG2-functional inhibitors at high consumption (see Stack-level contradictions). - No major direct ABCG2 interaction at dietary doses.

Practical note: Fermentation naturally produces these compounds. Eating traditional fermented foods (miso, soy sauce, kimchi, kombucha) provides dual benefits: living probiotics + NLRP3-suppressing metabolites. (Source: nlrp3-exploit-map.md)

Koji fermentation note: Home-made shio-koji and amazake (from wild-type A. oryzae) are practical fermented-food additions that also deliver digestive enzymes (amylase, protease, lipase). For the complete small-batch home protocol (koji-kin → koji rice → shio-koji / amazake), see Koji Home Fermentation. Yellow koji (A. oryzae) is the recommended strain for digestive-enzyme home use. (Mechanistic Extrapolation; source: koji-home-fermentation.md)

ABCG2 induction via fermentable fiber (source: abcg2-modulators.md): Fermentable fiber (resistant starch, inulin, GOS, beta-glucan) → colonic SCFA production → butyrate → PPARγ activation in enterocytes → ABCG2 transcriptional induction. Li et al. 2023 (Biomedicine & Pharmacotherapy, PMID 36948133) demonstrated that sodium butyrate in a hyperuricemic mouse model decreased serum UA AND restored intestinal ABCG2 expression. (Animal Model; source: abcg2-modulators.md) For Q141K-positive gout patients (~30–50% of the gout population), butyrate also rescues the Q141K variant's trafficking defect via HDAC inhibition — a separate, additive mechanism. DASH diet clinical data: 0.25 mg/dL mean UA reduction (0.73 mg/dL in patients with baseline UA ≥8 mg/dL) attributable to the fiber/ABCG2 axis (Juraschek et al. 2021, Arthritis & Rheumatology, PMID 33615722; Clinical Trial). Aim ≥25–30 g fermentable fiber/day for meaningful ABCG2 induction.

Cost: Negligible to modest ($5–10/week for specialty fermented products)

Discussion with Doctor: Disulfiram or Tranilast¶

Timeline: Schedule rheumatology or primary care visit in next 2–4 weeks

Talking points: 1. You're interested in exploring GSDMD pathway inhibition for gout flare prevention 2. Disulfiram is a 70-year safety record, FDA-approved drug with specific GSDMD-blocking activity 3. Tranilast is approved in Asia with clinical data in gout; worth exploring if willing to use international pharmacy 4. Neither is standard-of-care but both have mechanism-based rationale and published clinical efficacy in gout

What to expect: Many rheumatologists will be unfamiliar with these mechanisms but may be willing to discuss as off-label options, especially if you share the published papers.

Section 3: FUTURE (Dependent on Engineered Strains)¶

These become available as Open Enzyme [[engineered-yeast-uricase]] and [[engineered-koji-protocol]] strains are validated and deployed.

Engineered Yeast (S. cerevisiae or S. boulardii) — Uricase¶

Category: Living Therapeutic / Engineered Probiotic

Mechanism: Expresses uricase in gut lumen; degrades uric acid in place, creating a concentration sink that pulls systemic uric acid into intestine for degradation (Source: [[engineering-yeast-uricase-proposal]], [[open-enzyme-vision]])

Population context: Designed for under-excreter gout patients (~90% of gout population). Particularly relevant for patients with androgen-suppressed ABCG2 (TRT, SERM, AAS users) and Q141K-positive carriers — the populations where the gut-lumen-sink works hardest. Pre-clinical only; population stratification will be empirically refined in Phase 2 animal and Phase 3 human work.

Dosing range: TBD from Phase 2 animal studies; likely 10–20g dried yeast powder daily or equivalent live cells

Format: - Dried/lyophilized powder in capsules - Fermented beverage (kvass, water kefir, kombucha-style with engineered yeast) - Nutritional yeast sprinkled on food

Contraindications: TBD. Anticipated: severe immunocompromise (live probiotic risk), prior reaction to S. cerevisiae or S. boulardii (rare), active gut barrier disease (theoretical translocation risk for live probiotics). Pregnancy: no data; live engineered probiotic in pregnancy will require dedicated safety work.

Drug interactions: TBD. Anticipated minimal small-molecule pharmacokinetic interactions; functional interactions with the gut-lumen-sink axis are the relevant question (see Stack-level contradictions).

Dose-dependent risk profile: TBD from validation experiments.

Stack interactions (within this catalog): - Antagonism by ABCG2 inhibitors in stack: curcumin, quercetin, EGCG, genistein at supplement-relevant doses functionally inhibit ABCG2 — the transporter the engineered uricase depends on for its mechanism. The platform thesis is pharmacologically antagonized by these compounds in androgen-dominant or Q141K-positive readers. See Stack-level contradictions section. - Synergy with butyrate / fermentable fiber, sulforaphane, indole-3-carbinol: all induce ABCG2 (Tier 1 inducers per abcg2-modulators.md) — open the gate on which the platform depends. Strong recommended pairing. - Synergy with carnosine: carnosine modulates URAT1/GLUT9 (renal); engineered uricase modulates gut UA pool — orthogonal additive.

Timeline to availability: Phase 1 in vitro validation (weeks 1–10), Phase 2 animal studies (weeks 12–24), Phase 3 self-experimentation (weeks 24+). Earliest realistic availability: late 2026.

Expected benefit: 15–30% reduction in serum uric acid; potential for eliminating need for allopurinol or febuxostat in responders

Cost: TBD (target: cost-of-fermentation pricing)

Engineered Koji (A. oryzae) — Dual-Enzyme (Digestive + Uricase)¶

Category: Living Therapeutic / Engineered Food Organism

Mechanism: - Native koji enzymes: lipase, acid-stable protease, amylase (digestive enzyme support for Lynn) - Engineered addition: A. flavus uricase (uric acid degradation for Brian) - Grown on rice, consumed as fermented food (e.g., amazake, koji rice)

Population context: Designed for dual-target use (gout under-excreter + EPI-pattern digestive insufficiency). Population-context particulars TBD from Phase ⅔ work.

Dosing range: TBD; likely 10–20g koji per day (equivalent to ~1 cup koji rice)

Format: - Fresh koji grown on rice (traditional fermentation) - Dried koji powder - Koji amazake (sweet rice beverage) - Koji in soup or side dishes

Contraindications: TBD. Aspergillus allergy (rare but documented for occupational exposures). Severe immunocompromise (live probiotic concern). Pregnancy: no engineered-strain data; wild-type koji is GRAS at any dietary level.

Drug interactions: TBD. Wild-type koji digestive enzymes may interact with certain pharmaceutical preparations (acid-stable protease + protein-bound drugs); functional rather than pharmacokinetic.

Dose-dependent risk profile: TBD.

Stack interactions (within this catalog): - Same ABCG2 antagonism / synergy pattern as engineered yeast. See Stack-level contradictions. - Resistant-starch substrate (rice) provides incidental fermentable fiber → colonic butyrate → PPARγ-mediated ABCG2 induction. Substrate selection for the engineered koji platform may be tunable for incremental SCFA yield. (Mechanistic Extrapolation; see abcg2-modulators.md §"Engineering implications.")

Timeline to availability: Phase 1 koji optimization (weeks 4–10), Phase 2 EPI model (weeks 12–18), Phase 3 human trial (weeks 20–32+). Earliest: Q2 2026 for validation, Q3–Q4 2026 for deployment.

Expected benefit: - Brian: 15–30% reduction serum uric acid, potential 50% reduction flare frequency - Lynn: Improved fat absorption, normalized GI symptoms, reduced inflammatory markers

Cost: TBD

Reference daily pattern (NOT a recommendation)¶

Framing note (2026-04-25 catalog refactor): The block below is one possible scheduling pattern, kept for reference, not a recommended daily protocol. It survived from a pre-catalog version of this page and is preserved because the dose-timing logic (fat-soluble with meals, peptide on rising, fiber away from minerals, etc.) is reusable. Do not read this as "the Open Enzyme stack." Compound selection should always be filtered by individual contraindications, drug interactions, and the Stack-level contradictions section below.

Morning (with breakfast): - Vitamin D3 (5,000–10,000 IU) + K2 (200 mcg) — with fat - Sulforaphane supplement (50 mg) OR raw broccoli sprouts (100g) - Quercetin phytosome (500 mg) - Omega-3 (high-DHA preferred for gout; 2g EPA+DHA) — with food - NAC (600 mg) — optional, can take on empty stomach if prefer - KPV nasal spray (200–300 mcg) — before breakfast

Midday: - Oridonin (50 mg) — with lunch - Exogenous BHB or MCT oil if not doing ketogenic diet (10–15g)

Evening (with dinner): - Omega-3 (2g EPA+DHA) — second dose - Cherry extract (8 oz juice concentrate or equivalent) - NAC (600 mg) — if split dosing

Intermittent Fasting Window: - Minimum 16:8 daily - One 24-hour fast weekly or biweekly (if tolerated; skip during active flares)

Optional/As Tolerated: - Fermented foods daily: natto, aged cheese, miso, kimchi, kombucha - Trehalose (5–10g) mixed into coffee or tea

PRN (As Needed During Prodrome of Flare): - Disulfiram (250 mg daily × 7–14 days) — if flare symptoms appear - Consider BPC-157 IM injection or intensify nasal spray dosing - Topical CBD+THC (1:1 ratio, high-mg/oz) + ice cycling — apply to affected joint; ice 10–15 min → apply topical → ice again 30–60 min later. CB2-mediated NLRP3 suppression + TRPV1 desensitization. Jurisdiction-dependent. (In Vitro/Animal Model mechanism; direct gout-flare RCT absent. source: gout-action-guide.md, cannabinoids-terpenes.md)

Evidence Level Summary¶

Compound	Evidence Level	Chokepoints Hit	Mechanism	Cost/Month
BHB/Ketones	Established	CP1, CP2, CP3	Direct NLRP3 inhibition	$0–40
Intermittent Fasting	Established	CP1, CP2, CP3	AMPK/mTOR/autophagy	Free
KPV peptide	Supported	CP1	NF-κB stabilization	$100–200
BPC-157	Established	CP1 (tissue repair)	Cytoprotection, NO modulation	Existing
Sulforaphane	Established	CP1, CP2	Nrf2/NF-κB crosstalk; ABCG2 inducer (gut-sink synergy)	$5–30
Oridonin	Established	CP1, CP2	NLRP3 covalent inhibitor (5.18 μM human IC50)	$30–60
Omega-3 (DHA-emphasis)	Animal Model (gout SPMs)	CP1, CP5a, CP5b	SPM precursors; RvD1/MaR1 direct gout evidence	$30–50
Cherry extract	Supported	CP1 (XO inhibition)	Anthocyanins	$20–30
NAC	Established	CP2	Glutathione replenishment	$10–15
Quercetin (Phytosome)	Established	CP6a (5-LOX 300 nM, primary), CP1, XO	5-LOX/LTB4 + NF-κB + XO; functional ABCG2 inhibitor (stack contradiction)	$15–25
EGCG (green tea)	Animal Model (MSU mouse, Lee 2019)	CP1, CP1a (TNFSF14), CP4, CP5a	Widest-spectrum natural compound; 4 of 7 chokepoints; hepatotox ceiling; functional ABCG2 inhibitor (stack contradiction; in vivo unresolved)	$15–25
Limonene (d-limonene)	Animal Model (MSU rat, Venkatesan 2025)	CP1, CP2	Nrf2 + TLR4 suppression	$15–25
Lactoferrin (bovine)	Animal + Clinical Ph3 (talactoferrin)	CP5	NLRP3/caspase-1/GSDMD axis; fills canakinumab gap	$30–60
Carnosine (L-carnosine)	Animal Model (HUA rat)	CP1, CP2, +urate	Dual UA + NLRP3 (unique in stack); androgen-axis aligned	$20–35
Tongkat Ali (Physta/LJ100)	Clinical Trial (T meta + UA RCT)	+urate (multi-target transporter + PRPS)	Dual T-up + UA-down (rare in class); URAT1↓, GLUT9↓, ABCG2↑, PRPS↓; NOT an XO inhibitor	$25–50
Beta-caryophyllene	Animal Model (MSU gout)	CP1, CP2	CB2 agonism / TLR4 / NLRP3	$15–30
Vitamin D3 + K2	Established	CP1	VDR activation	$10–15
Disulfiram	Established	CP6b	GSDMD pore blockade	~$30
Tranilast	Established	CP2	NACHT domain binding	$50–100
Fermented foods	Established	CP2, CP3	Spermidine/trehalose; soy-fermented = trace genistein (mild ABCG2 functional inhibitor at supplement-level intakes only)	$5–10
Engineered Yeast	Validated Ph2	Upstream (uric acid)	Direct degradation; depends on ABCG2 — stack contradictions apply	TBD 2026
Engineered Koji	Validated Ph2	Upstream + Digestive	Dual enzyme; depends on ABCG2 — stack contradictions apply	TBD 2026

Stack-level interactions¶

The per-compound entries above flag interactions one compound at a time. This section consolidates the patterns that emerge when multiple compounds are stacked — particularly the cases where the catalog as a whole pulls in opposing directions on a shared mechanism.

1. Stack-level contradictions: ABCG2-axis antagonism of the platform thesis¶

The engineered-uricase platform's gut-lumen-sink mechanism depends on intestinal ABCG2 to actively secrete urate from blood into gut lumen, where the engineered uricase degrades it. Several compounds in this catalog at typical supplement doses are functional inhibitors of ABCG2 — they pharmacologically antagonize the platform thesis, particularly in male / androgen-dominant / Q141K-positive readers (the dominant gout demographic).

Detailed mechanism, primary citations, and tissue-selectivity discussion in abcg2-modulators.md. Summary table:

Compound	ABCG2 effect	Evidence	Net effect on gut sink	Stack flag
Curcumin	Functional BCRP/ABCG2 inhibitor in vitro (Ki ~5–10 μM)	Established in vitro pharmacology (multiple labs)	Likely negative acutely at 500–1000 mg supplement doses (gut concentrations easily reach Ki)	Antagonist
Quercetin	Substrate/inhibitor at low μM (functional inhibition); transcriptional ABCG2 upregulation reported in chronic-dosing animal studies (mixed)	In vitro + Animal Model (mixed direction by chronicity)	Probably negative acutely; chronic effect unresolved	Antagonist (acute)
EGCG	Functional BCRP inhibitor in pharmacology assays. Yu 2024 (PMID 38757391) showed mouse PO-induced hyperuricemic model net-favorable effect on ABCG2/URAT1/GLUT9 expression in vivo — direction opposite to in vitro inhibition	Pharmacology in vitro vs. Animal Model in vivo (contradicts)	Unresolved — net clinical effect on gut sink in androgen-dominant patients pending direct measurement	Antagonist (in vitro), Synergist (some animal in vivo)
Genistein / soy isoflavones	Established BCRP substrate-inhibitor	Pharmacology literature	Dietary intake from natto/miso/tempeh: clinically negligible. Supplement-grade isoflavone capsules: meaningful inhibition at 50–100 mg/day	Antagonist (supplement-grade only; food-level fine)

Note: Curcumin is not currently a separate entry in this catalog — it's flagged here because it is the prototypical functional ABCG2 inhibitor in this class, and is frequently stacked alongside the catalog compounds in real gout-supplement use. If curcumin is added in the future, it carries the same stack-contradiction flag as quercetin.

Risk-tier stratification (added 2026-04-27 per synthesis Pass 3 review — "blanket warnings undermine compliance when the actual risk is genotype/dose-dependent"):

User profile	ABCG2 status	Risk tier	Practical implication
Q141K homozygote + androgen-suppressed (TRT / SERM / AAS) + high-dose flavonoid (>500 mg quercetin OR >600 mg EGCG OR >500 mg curcumin)	Triple-hit suppressed	Highest concern	Gut sink may be functionally closed during dose window. Pause inhibitor flavonoids until ABCG2-axis status is established; favor inducers (sulforaphane, fermentable fiber → butyrate per abcg2-modulators.md §6).
Q141K heterozygote OR androgen-dominant (high-T, no SERM) + supplement-grade flavonoid	One axis suppressed + acute pharmacological inhibition	High concern	Meaningful gut-sink narrowing during the dose window. Time inhibitor flavonoids away from urate spikes (post-fructose meals, peri-flare). Acceptable with UA monitoring.
Wild-type ABCG2 + supplement-grade flavonoid	Pharmacological inhibition only	Moderate concern	Net effect is dose- and chronicity-dependent. Watch UA trajectory after introduction; discontinue or down-titrate if UA rises.
Any genotype + dietary-level flavonoid (onions, tea, turmeric, fermented soy at normal food portions)	Sub-Ki gut concentrations	Minimal concern	No restriction. Food-level intake is unlikely to be clinically significant for the gut sink.

Stratification matters because a blanket "avoid quercetin" message undermines compliance for the largest cohort (wild-type genotype, dietary intake) where the risk is essentially zero. The clinically meaningful signal concentrates in androgen-suppressed Q141K-positive readers at supplement-grade doses.

Practical inference for high-T or Q141K-positive readers: avoid high-dose curcumin and quercetin acutely when the gut sink matters most (post-meal urate spikes, fructose challenges, peri-flare). Dietary-level intake (turmeric in food, onions, tea, fermented soy at normal portions) is unlikely to be clinically problematic; supplement-grade doses are the concern.

Counter-balancing inducers in the catalog (Tier 1 ABCG2 inducers per abcg2-modulators.md): - Sulforaphane (Nrf2 axis) — gut-enriched - Fermentable-fiber-derived butyrate (PPARγ axis; not a discrete catalog entry, but fermented-foods + dietary fiber adjacent) — strongest evidence (Juraschek DASH 2021, Li 2023) - Indole-3-carbinol / DIM, AhR-active probiotic strains — gut-enriched (not currently discrete catalog entries; flagged as adjacent)

A reader most concerned about the gut-lumen-sink (e.g., on TRT or known Q141K-positive) should preferentially weight inducers over inhibitors when considering catalog entries.

2. Stack-level synergies and redundancies¶

These are cases where multiple catalog compounds converge on the same mechanism — additive at low fractional saturation, redundant at high fractional saturation.

Nrf2 activator cluster (sulforaphane + quercetin + oridonin + limonene + omega-3 metabolites): all five drive Nrf2 transcriptional activation. At individual supplement doses each is sub-saturating; layering produces cumulative effect with diminishing returns. Combining all five is redundant beyond a certain ceiling — pick 2–3 for the Nrf2 axis rather than every one.

NF-κB priming block cluster (KPV + sulforaphane + EGCG + quercetin + carnosine + curcumin (if added)): all six suppress NF-κB priming via different molecular routes. Mechanism-orthogonal at the molecular level (peptide/IκB-α stabilization vs. proteasome inhibition vs. transcriptional vs. ROS-dependent), so additive at the pathway level. Again, diminishing returns past 3–4 stacked.

XO inhibition cluster (cherry + quercetin + EGCG): all three modestly inhibit xanthine oxidase. Additive on UA production; layering with allopurinol or febuxostat may exceed XO-suppression target.

CP2 NLRP3-assembly orthogonality (oridonin + BCP + tranilast + dapansutrile (if available) + BHB): distinct molecular touch-points (Cys279 covalent / CB2-TLR4 / NACHT direct / NACHT direct / K+ efflux). Genuinely additive; not a redundancy cluster.

SPM resolution + peptide cytoprotection (omega-3 DHA-emphasis + KPV + BPC-157): complementary at the resolution phase (CP5). Resolution-phase mechanism (efferocytosis, M1→M2 switch) is undersupplied in most stack designs — this triad is one of the genuine non-redundant synergies.

Autophagy axis (intermittent fasting + spermidine/trehalose from fermented foods): mechanism-aligned (TFEB / mTOR-independent autophagy). Additive within the same axis.

3. Stack-level safety amplifications¶

Cases where multiple catalog compounds compound a single safety risk.

Hepatotoxicity stacking (EGCG + acetaminophen + alcohol + disulfiram + high-dose curcumin if added): all converge on hepatic stress. The 86 nM 20S proteasome IC50 of EGCG sets a hepatotoxicity dose ceiling at ~800 mg/day; layering with any other hepatotoxic input shifts the ceiling lower. Periodic ALT/AST monitoring is conservative for any reader running EGCG + a second hepatotoxic input chronically.

Bleeding risk stacking (omega-3 ≥3g/day + EGCG + quercetin + warfarin / DOACs / antiplatelets): the polyphenol cluster has modest antiplatelet effects that aggregate with omega-3's platelet inhibition. INR shifts (on warfarin) are documented for omega-3 alone; adding EGCG and quercetin is additive. Practical: at the upper end of stack doses, surgical / dental procedures should trigger a 7–14 day hold on the polyphenol + omega-3 layer.

CYP3A4 inhibition stacking (quercetin + EGCG + oridonin + d-limonene at chronic doses): all four show in vitro CYP3A4 inhibition at gut-relevant concentrations. Simvastatin, tacrolimus, cyclosporine, calcium channel blockers, and direct oral anticoagulants are the highest-leverage drug classes affected. A reader on any narrow-therapeutic-index CYP3A4 substrate should avoid layering 3+ of these compounds chronically without therapeutic drug monitoring.

Disulfiram-ethanol amplification (disulfiram + kombucha / koji-fermented foods + alcohol-containing OTC preparations): any residual ethanol input can trigger disulfiram-ethanol reaction. Practical: disulfiram users should avoid kombucha entirely and treat any koji-derived fermented foods as a per-batch ethanol-content question.

Vitamin K2 + warfarin (already flagged at compound level): worth re-flagging at the stack level because natto (fermented foods entry) is one of the highest natural K2 sources known. Warfarin patients eating natto plus taking K2 supplements compound the warfarin antagonism.

Hypercalcemia stacking (D3 + K2 + thiazide diuretic): D3 increases calcium absorption; thiazides reduce renal calcium excretion. K2 directs calcium to bone but does not negate the absorption × retention compounding. Patients on thiazides at high D3 supplemental doses should monitor serum calcium.

Practical Implementation¶

(Implementation discussion below remains catalog-level — i.e., "if a reader were to consider these compounds, here's a rough sequencing logic." It is not a recommended protocol; see the "Reference daily pattern" framing above.)

Week 1 (low-friction entry): - Begin BHB/ketones (dietary or supplement) - Start intermittent fasting (16:8 minimum) - Add sulforaphane + quercetin (both are safe, rapid onset); note quercetin's ABCG2-functional-inhibitor flag for androgen-dominant readers - Continue BPC-157 nasal spray (already in use)

Week 2–3: - Add KPV nasal spray (order from supplier) - Add omega-3 (DHA-emphasis) and NAC - Add cherry extract - Add oridonin (order from Chinese herb supplier or research chemical) - Begin raw broccoli sprout protocol (if not using supplement form)

Week 4+: - Introduce vitamin D3 + K2 (warfarin-incompatible without monitoring) - Consider fermented foods (natto 1–2×/week minimum, with same warfarin flag) - Schedule physician visit to discuss disulfiram/tranilast if appropriate

Ongoing: - Track serum uric acid monthly (initially), then every 3 months - Monitor flare frequency/severity in journal - Re-read Stack-level contradictions section before adding curcumin or high-dose isoflavones - Periodic ALT/AST monitoring for any reader running EGCG ≥600 mg/day chronically

This catalog is a living document. Update as [[validation-experiments]] (Phase 2 & 3) generate new data. Individual compounds may be emphasized or de-emphasized based on personal context, tolerability, and efficacy.

Not medical advice. All use should be supervised by a physician.